AMRI optimizes global operations to improve continuous supply chain across its businesses

AMRI (NASDAQ: AMRI) today announced that it has implemented several changes to further optimize global business operations in order to enhance continuity from early development through to commercial supply and accelerate the company's global growth objectives.

The realigned structure will continue to improve performance and reliability by maximizing the value of AMRI's various integrated services for customers. Enhancing the link between operations and core business segments, together with the corporate-level support functions, will foster real-time decision making, appropriate resource prioritization and integration necessary to create a more adaptive, efficient and customer-centric global pharmaceutical services company.

Steven R. Hagen, Ph.D., Senior Vice President of Manufacturing and Pharmaceuticals, has assumed oversight of AMRI's global operations infrastructure ensuring that the manufacturing and development operations execute efficiently, safely and to AMRI's quality standards. With this change, AMRI has improved line-of-sight of all global operations across all of its service offerings and all of its locations.

George Svokos, Senior Vice President Sales and General Manager-API, has assumed responsibility for a newly created Commercial function as Chief Commercial Officer, which comprises Sales and Marketing, Project Management and Supply Chain under one roof. In addition to leading the Commercial function, Mr. Svokos will continue to spearhead AMRI's integrated API Manufacturing offering that includes Chemical Development and Large Scale API Manufacturing.

William S. Marth, AMRI's president and chief executive officer, said, "We are committed to continually improving our business operations, and are confident that streamlining our global operations will further enhance our ability to provide customers with a fluid, continuous supply chain across all of our businesses. In addition, the optimization and globalization of customer relations and project management strengthens our ability to manage the customer interface."

In tandem with the realignment, AMRI also announced the following senior management promotions:

Milton Boyer was promoted to Senior Vice President of Drug Product Manufacturing, from his former role as VP of Parenterals. Mr. Boyer's expertise from OsoBio will be applied across all phases of Drug Product, which spans from Pre-Formulation and Formulation Development all the way through to Late Phase and Commercial Parenteral Manufacturing.

Christopher Conway was promoted to Senior Vice President of Global Sales and Marketing, and is responsible for all global sales, marketing and customer operations functions. Mr. Conway, who joined AMRI in 2008, was most recently Vice President of Global Sales and Marketing. Before joining AMRI, Mr. Conway held sales and leadership positions of increasing responsibility at Johnson and Johnson.

To effectively support the growing interface between Chemical Development and API and best align AMRI's resources to effectively manage and transition customer projects, Rajesh Shenoy, Ph.D., was promoted to Senior Director of Global Chemical Development. Dr. Shenoy has been with AMRI since 1998 in various roles of increasing responsibility. Most recently, Dr. Shenoy was Senior Director of Global Project Management. Dr. Shenoy earned a Ph.D. in Organic Chemistry at the University of Akron and conducted postdoctoral research at Kent State University.